We have demonstrated that small tumour size, lack of ER expression and high TIL values may help to predict the response of HER2+ tumours to NAT, whereas expression of PR could be a good predictor of resistance to NAT in TN tumours. The gene discussed is BRD2; the disease is neoplasm.